Почетна › Рак јајника › Alabama
Kliničke studije za Рак јајника u državi Alabama
29 studija za Рак јајника traži učesnike na lokacijama u državi Alabama.
Gradovi u državi Alabama
Zvanični tekst studije (na engleskom)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- University of Alabama at Birmingham Cancer Center, Birmingham
- University of South Alabama Mitchell Cancer Institute, Mobile
Тражи се учесникФаза 2
Сви узрасти · Оба пола · Ажурирано 12. 11. 2026. · NCT05564377A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- University of Alabama at Birmingham ( Site 0006), Birmingham
Тражи се учесникФаза 3
Узраст 18 и старији · Жене · Ажурирано 10. 11. 2026. · NCT06824467A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- University of Alabama - Birmingham ( Site 0058), Birmingham
Тражи се учесникФаза 3
Узраст 18 и старији · Жене · Ажурирано 10. 11. 2026. · NCT07318558Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- University of Alabama at Birmingham Cancer Center, Birmingham
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT06580314Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
- The University of Alabama at Birmingham, Birmingham
Тражи се учесникФаза 2
Узраст 18 и старији · Жене · Ажурирано 6. 11. 2026. · NCT06787612A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- University of Alabama at Birmingham Cancer Center, Birmingham
Тражи се учесник
Узраст од 35 до 50 · Жене · Ажурирано 6. 11. 2026. · NCT04251052INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study
- University of Alabama at Birmingham, Birmingham
Тражи се учесникНаводи исплату за учеснике
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07671937A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- University of Alabama at Birmingham, Birmingham
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07213804A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital, Birmingham
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06760819FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- University of Alabama at Birmingham, Birmingham
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT06303505A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Site 0170-USA Mitchell Cancer Institute, Mobile
Тражи се учесникФаза 2
Узраст 18 и старији · Жене · Ажурирано 30. 10. 2026. · NCT05128825A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- University of Alabama at Birmingham, Birmingham
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 22. 10. 2026. · NCT04657068A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- University of Alabama at Birmingham (UAB) Hospital /ID# 274793, Birmingham
- Usa Mitchell Cancer Institute /ID# 276022, Mobile
Тражи се учесникФаза 2
Узраст 18 и старији · Жене · Ажурирано 20. 10. 2026. · NCT06890338Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- University of Alabama Birmingham, Birmingham
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT06293898A Study of Sovilnesib in Subjects With Ovarian Cancer
- The University of Alabama at Birmingham, Birmingham
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT06084416177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- Dothan Hematology & Oncology, Dothan
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 1. 10. 2026. · NCT07189871Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- University of Alabama_6th Ave, Birmingham
Тражи се учесникФаза 1/2
Узраст 18 и старији · Жене · Ажурирано 25. 9. 2026. · NCT03564340DESTINY-PANTUMOUR04
- Research Site, Birmingham
Тражи се учесникОпсервациона студија
Узраст од 18 до 130 · Оба пола · Ажурирано 25. 9. 2026. · NCT07124000A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Usa Health Mitchell Cancer Institute, Mobile
Тражи се учесникФаза 2
Узраст од 18 до 99 · Жене · Ажурирано 15. 9. 2026. · NCT07023627ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- University of Alabama at Birmingham, Birmingham
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 14. 9. 2026. · NCT05059444Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- The University of South Alabama, Mitchell Cancer Institute, Mobile
Тражи се учесникФаза 3
Узраст 18 и старији · Жене · Ажурирано 26. 8. 2026. · NCT05281471Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's Hospital of Alabama, Birmingham
Тражи се учесникФаза 1/2
12 Months – 30 Years · Оба пола · Ажурирано 25. 8. 2026. · NCT04851119Study of NTB-928 in R/R OC
- The University of Alabama, Birmingham
Тражи се учесникФаза 1
Узраст 18 и старији · Жене · Ажурирано 20. 8. 2026. · NCT07690189The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons
- University of Alabama at Birmingham, Birmingham
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
Узраст од 18 до 99 · Жене · Ажурирано 29. 7. 2026. · NCT03538665Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
- 004, Birmingham
Тражи се учесникФаза 2
Узраст 18 и старији · Жене · Ажурирано 16. 7. 2026. · NCT06906341Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- University of Alabama at Birmingham Womens & Infants Center, Birmingham
Тражи се учесникФаза 2
Узраст 18 и старији · Жене · Ажурирано 14. 7. 2026. · NCT04606914Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro
- O'Neal Comprehensive Cancer Center at UAB, Birmingham
Тражи се учесникФаза 2
Узраст 18 и старији · Жене · Ажурирано 29. 6. 2026. · NCT05952453Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
- University of Alabama at Birmingham, Birmingham
- University of South Alabama, Mobile
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 30. 4. 2026. · NCT05297734SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Birmingham
- Massive Bio SYNERGY-AI site, Mobile
Тражи се учесникОпсервациона студија
Сви узрасти · Оба пола · Ажурирано 28. 10. 2025. · NCT03452774Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.